TISIDB

Summary
Symbol	B3GAT3
Name	beta-1,3-glucuronyltransferase 3
Aliases	GlcAT-I; glucuronosyltransferase I; galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 3; bet ......
Chromosomal Location	11q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Golgi apparatus membrane Single-pass type II membrane protein Golgi apparatus, cis-Golgi network
Domain	PF03360 Glycosyltransferase family 43
Function	Glycosaminoglycans biosynthesis (PubMed:25893793). Involved in forming the linkage tetrasaccharide present in heparan sulfate and chondroitin sulfate. Transfers a glucuronic acid moiety from the uridine diphosphate-glucuronic acid (UDP-GlcUA) to the common linkage region trisaccharide Gal-beta-1,3-Gal-beta-1,4-Xyl covalently bound to a Ser residue at the glycosaminylglycan attachment site of proteoglycans. Can also play a role in the biosynthesis of l2/HNK-1 carbohydrate epitope on glycoproteins. Shows strict specificity for Gal-beta-1,3-Gal-beta-1,4-Xyl, exhibiting negligible incorporation into other galactoside substrates including Galbeta1-3Gal beta1-O-benzyl, Galbeta1-4GlcNAc and Galbeta1-4Glc. Stimulates 2-phosphoxylose phosphatase activity of PXYLP1 in presence of uridine diphosphate-glucuronic acid (UDP-GlcUA) during completion of linkage region formation (PubMed:24425863).

> Gene Ontology [ TOP ]
Biological Process	GO:0006022 aminoglycan metabolic process GO:0006023 aminoglycan biosynthetic process GO:0006024 glycosaminoglycan biosynthetic process GO:0006029 proteoglycan metabolic process GO:0006486 protein glycosylation GO:0006790 sulfur compound metabolic process GO:0009100 glycoprotein metabolic process GO:0009101 glycoprotein biosynthetic process GO:0015012 heparan sulfate proteoglycan biosynthetic process GO:0030166 proteoglycan biosynthetic process GO:0030201 heparan sulfate proteoglycan metabolic process GO:0030203 glycosaminoglycan metabolic process GO:0030204 chondroitin sulfate metabolic process GO:0032386 regulation of intracellular transport GO:0032388 positive regulation of intracellular transport GO:0033157 regulation of intracellular protein transport GO:0043413 macromolecule glycosylation GO:0044272 sulfur compound biosynthetic process GO:0050650 chondroitin sulfate proteoglycan biosynthetic process GO:0050651 dermatan sulfate proteoglycan biosynthetic process GO:0050654 chondroitin sulfate proteoglycan metabolic process GO:0050655 dermatan sulfate proteoglycan metabolic process GO:0051222 positive regulation of protein transport GO:0070085 glycosylation GO:0090316 positive regulation of intracellular protein transport GO:1903510 mucopolysaccharide metabolic process GO:1903829 positive regulation of cellular protein localization GO:1904951 positive regulation of establishment of protein localization
Molecular Function	GO:0008047 enzyme activator activity GO:0008194 UDP-glycosyltransferase activity GO:0015018 galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase activity GO:0015020 glucuronosyltransferase activity GO:0016757 transferase activity, transferring glycosyl groups GO:0016758 transferase activity, transferring hexosyl groups GO:0019208 phosphatase regulator activity GO:0019211 phosphatase activator activity GO:0019888 protein phosphatase regulator activity GO:0072542 protein phosphatase activator activity
Cellular Component	GO:0005801 cis-Golgi network

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa00532 Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate hsa00534 Glycosaminoglycan biosynthesis - heparan sulfate / heparin hsa01100 Metabolic pathways
Reactome	R-HSA-1971475: A tetrasaccharide linker sequence is required for GAG synthesis R-HSA-1793185: Chondroitin sulfate/dermatan sulfate metabolism R-HSA-1630316: Glycosaminoglycan metabolism R-HSA-1638091: Heparan sulfate/heparin (HS-GAG) metabolism R-HSA-1430728: Metabolism R-HSA-71387: Metabolism of carbohydrates

Summary
Symbol	B3GAT3
Name	beta-1,3-glucuronyltransferase 3
Aliases	GlcAT-I; glucuronosyltransferase I; galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 3; bet ......
Chromosomal Location	11q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between B3GAT3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	B3GAT3
Name	beta-1,3-glucuronyltransferase 3
Aliases	GlcAT-I; glucuronosyltransferase I; galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 3; bet ......
Chromosomal Location	11q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of B3GAT3 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	Second most enriched score: 0.56	Sensitive to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	B3GAT3
Name	beta-1,3-glucuronyltransferase 3
Aliases	GlcAT-I; glucuronosyltransferase I; galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 3; bet ......
Chromosomal Location	11q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of B3GAT3 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.18	0.555
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.22	0.929
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.145	0.939
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.432	0.294
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.391	0.819
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.485	0.825
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.072	0.849
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.162	0.907
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.032	0.984
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.24	0.893
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.197	0.941
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.087	0.179

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of B3GAT3 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	0	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	B3GAT3
Name	beta-1,3-glucuronyltransferase 3
Aliases	GlcAT-I; glucuronosyltransferase I; galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 3; bet ......
Chromosomal Location	11q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of B3GAT3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	B3GAT3
Name	beta-1,3-glucuronyltransferase 3
Aliases	GlcAT-I; glucuronosyltransferase I; galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 3; bet ......
Chromosomal Location	11q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of B3GAT3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by B3GAT3. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	B3GAT3
Name	beta-1,3-glucuronyltransferase 3
Aliases	GlcAT-I; glucuronosyltransferase I; galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 3; bet ......
Chromosomal Location	11q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of B3GAT3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	B3GAT3
Name	beta-1,3-glucuronyltransferase 3
Aliases	GlcAT-I; glucuronosyltransferase I; galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 3; bet ......
Chromosomal Location	11q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of B3GAT3 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	B3GAT3
Name	beta-1,3-glucuronyltransferase 3
Aliases	GlcAT-I; glucuronosyltransferase I; galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 3; bet ......
Chromosomal Location	11q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between B3GAT3 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	B3GAT3
Name	beta-1,3-glucuronyltransferase 3
Aliases	GlcAT-I; glucuronosyltransferase I; galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 3; bet ......
Chromosomal Location	11q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting B3GAT3 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting B3GAT3.

ID	Name	Drug Type	Targets	#Targets
DB03041	UDP-alpha-D-glucuronic acid	Small Molecule	B3GAT3, GALE	2
DB03435	Uridine-5'-Diphosphate	Small Molecule	ABO, B3GAT1, B3GAT3, CMPK1, EXTL2, GLT6D1, GYG1	7

Browse B3GAT3